Doran, W. ., Tunnicliffe, L. ., Muzambi, R. ., Rentsch, C. T., Bhaskaran, K. ., Smeeth, L. ., … Warren-Gash, C. . (2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548
Glucose
Lai, H. T. M., Chang, K. ., Sharabiani, M. T. A., Valabhji, J. ., Gregg, E. W., Middleton, L. ., … Vamos, E. P. (2023). Twenty-year trajectories of cardio-metabolic factors among people with type 2 diabetes by dementia status in England: a retrospective cohort study. Eur J Epidemiol. http://doi.org/10.1007/s10654-023-00977-7
Brunetti, V. C., St-Jean, A. ., Dell’Aniello, S. ., Fisher, A. ., H. Y. Yu, O. ., Bugden, S. C., … Filion, K. B. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. BMC Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207–2214. http://doi.org/10.1111/dom.14437
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189